Remission of treatment-resistant obsessive-compulsive disorder with 600 milligrams of fluvoxamine daily: a case report : International Clinical Psychopharmacology

Secondary Logo

Journal Logo

Advanced Search
Case Reports

Remission of treatment-resistant obsessive-compulsive disorder with 600 milligrams of fluvoxamine daily: a case report

Kocamer Şahin, Şengül; Demir, Bahadir; Altindağ, Abdurrahman

Author Information

Department of Psychiatry, Gaziantep University, Faculty of Medicine, Gaziantep, Turkey

Received 14 October 2022 Accepted 11 December 2022.

Correspondence to Şengül Kocamer Şahin, MD, Department of Psychiatry, Gaziantep University Şahinbey Research and Application Hospital, University Boulevard, 27310, Gaziantep, Turkey, Tel: +90 (533) 6636876; e-mail: [email protected]

International Clinical Psychopharmacology 38(4):p 273-274, July 2023. | DOI: 10.1097/YIC.0000000000000458

Abstract

First-line drugs for obsessive-compulsive disorder (OCD) pharmacotherapy are selective serotonin reuptake inhibitors (SSRI). The medication must be continued for at least 12 weeks at an effective dosage to find the most effective SSRI. For treatment, the drug dose should be titrated to the highest tolerated dose. The manufacturer’s recommended maximum dose of fluvoxamine is 300 mg per day. We reported remission after about 1 month of 600 mg (high dose) fluvoxamine, which was tolerated by a patient with OCD. The patient continued at this dose for 3 months and remained in remission.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid